ESR1 and breast carcinoma: Understanding the complex interaction among pro‐angiogenic factors (ANG/Tie‐2/VEGF‐C) and their relationship with ER or HER‐2 status underscores the clinical relevance of these biomarkers in detecting ALNM in breast cancer patients.